Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-10-10
2006-10-10
Chang, Celia (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S301000
Reexamination Certificate
active
07119205
ABSTRACT:
The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.
REFERENCES:
patent: 5378679 (1995-01-01), Nuebling et al.
patent: 5602144 (1997-02-01), Gottschlich et al.
Buchstaller et al., Thieno[2,3-b]pyridinoes as Antagonists on the Glycine Site of the N-methyl-D-aspartate Receptor—Binding Studies, Molecular Modeling and Structure-Activity-Relationships, Scientia Pharmaceutica 68(1):3-14 (2000).
Bergeron, R., et al., “Effect of 5-Aminoimidazole-4-Carboxamide-1-[beta]-D-Ribofuranoside Infusion on In Vivo Glucose and Lipid Metabolism in Lean and Obese Zucker Rats”,Diabetes, 50(5):1076-1082 (2001).
Blázquez, C., et al., “The AMP—Activated Protein Kinase is Involved in the Regulation of Ketone Body Production by Astrocytes”,Journ of Neurochemistry, 73:1674-1682 (1999).
Carling, D., et al., “A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis”,FEB, 223(2):217-222 (1987).
Corton, J. M., et al., “5-Aminoimidazole-4-carboxamide ribonucleoside—A specific method for activating AMP-activated protein kinase in intact cells?”,Eur. J. Biochem., 229:558-565 (1995).
Buhl, Esbes S., et al., “Long-Term AICAR administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome”,Diabetes, 51(7):2199-2206 (2002).
Garton, A. J., et al., “Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase”,Eur. J. Biochem., 179:249-254 (1989).
Halseth, A. E., et al., “Acute and chronic treatment of ob/ob and db/db mice with AlCAR decreases blood glucose concentrations”,Biochem&Biophys Res Comm., 294:798-805 (2002).
Hardie, D. G., & Hayley, S. A., “AMP-activated protein kinase: the energy charge hypothesis revisited”,BioEssays, 23(12):1112-1119 (2001).
Hwang, K-J., et al., “4-Hydroxy-6-Oxo-6,7-Dihydro-Thieno[2,3-b] Pyrimidine Derivatives: Synthesis and Their Biological Evaluation for the Glyciine Site Acting on theN-Methyl-D-Aspartate (NMDA) Receptor”,Arch Pharm Res., 24(4):270-275 (2001).
Isabelle, L., et al., “Hepatocyte Nuclear Factor-4[alpha] Involved in Type 1 Maturity-Onset Diabetes of the Young Is a Novel Target of AMP-Activated Protein Kinase”,Diabetes, 50(7):1515-1521 (2001).
Kemp et al., “AMP-activated protein kinase, super metabolic regulator,” Biochem. Soc. Transactions 31:162-168 (2003).
Lockhead, P., et al., “5-Aminoimidazole-4-Carboxamide Riboside Mimics the Effects of Insulin on the Expression of the 2 Key Gluconeogenic Genes PEPCK and Glucose-6-Phosphatase”,Diabetes, 49(6):896-903 (2000).
Minokoshi, Y., et al., “Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase”,Nature, 415:339-343 (2002).
Mu, J., et al., “A Role of AMP-Activated Protein Kinase in Contraction and Hypoxia-Regulated Glucose Transport in Skeletal Muscle”,Molecular Cell, 7:1085-1094 (2001).
Muoio, D. M., et al., “AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence thatsn-glycerol-3-phosphate acyltransferase is a novel target”,Biochem J., 338:783-791 (1999).
Musi, N., & Goodyear, L. J., “Targeting the AMP-Activated Protein Kinase for the Treatment of Type 2 Diabetes”,Current Drug Targets-Imm. End&Metabo. Disor., 2:119-127 (2002).
Musi, N., et al., “Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes”,Diabetes, 51(7):2074-2081 (2002).
Saha, A. K., et al., “Activation of Malonyl-CoA Decarboxylase in Rat Skeletal Muscle by Contraction and the AMP-activated Protein Kinase Activator 5-Aminomidazole-4-carboxamide-1-B-D-ribofuranoside”,J. Biol. Chem., 275(32):24279-24283 (2000).
Song, X. M., et al., “5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice”,Diabetologia, 45:56-65 (2002).
Tomas, E., et al., “Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation”,PNAS, 99*25):16309-16313 (2002).
Yamauchi, T., et al., “Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase”,nature medicine, 8(11):1288-1295 (2002.
Chen, Z-P., et al., “AMP-activated protein kinase phosphorylation of endothelial NO synthase”,FEBS Letters, 443:285-289 (1999).
Zhou, G., et al., “Role of AMP-activated protein kinase in mechanism of metformin action”,The Journ of Clin Invest., 108(8):1167-1174 (2001).
Zhou, M., et al., “UCP-3 expression in skeletal muscle: effects, hypoxia, and AMP-activated protein kinase”,Am J Physiol Endoc Metab., 279:E622-E629 (2000).
Clark Richard F.
Cool Barbara L.
Frevert Ernst U.
Gu Yugui
Hansen Todd M.
Abbott Laboratories
Chang Celia
Corbin Johanna M.
Parial Andrew M.
LandOfFree
Thienopyridones as AMPK activators for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyridones as AMPK activators for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyridones as AMPK activators for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3642338